Polyrizon Files for U.S. Patent Application to Expand IP Moat Around Intranasal Drug-Delivery PlatformGlobeNewsWire · Oct 5, 2026
Polyrizon Enrolls First Patient in U.S. Clinical Study of NASARIX (PL-14) Allergy BlockerGlobeNewsWire · Sep 22, 2026
Polyrizon Ltd. Announces Closing of $4.0 Million Registered Direct Offering and Private PlacementGlobeNewsWire · Sep 4, 2026
Polyrizon Ltd. Announces $4.0 Million Registered Direct Offering and Private PlacementGlobeNewsWire · Sep 3, 2026
Polyrizon Completes All Five U.S. Site Contracts for NASARIX™ First-in-Human Allergy StudyGlobeNewsWire · Sep 2, 2026
Polyrizon Completes Clinical Site Network for NASARIX™ Study and Advances Toward Patient EnrollmentGlobeNewsWire · Aug 20, 2026Polyrizon Ltd. is an Israeli biotechnology firm specializing in the creation of medical device hydrogels, delivered as nasal sprays. These innovative sprays are designed to form a protective barrier within the nasal cavity, preventing viruses and allergens from attaching to the nasal epithelial tissue. Its current development pipeline features several targeted solutions, including PL-14, formulated to block nasal allergies; PL-15, aimed at combating COVID-19; and PL-16, for influenza prevention.